Affinage

FBXO45

F-box/SPRY domain-containing protein 1 · UniProt P0C2W1

Length
286 aa
Mass
30.6 kDa
Annotated
2026-06-09
34 papers in source corpus 24 papers cited in narrative 24 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FBXO45 is an atypical F-box protein that operates as the substrate-recognition adaptor of a non-canonical ubiquitin ligase: a substitution in its Cul1-binding sequence precludes formation of a classical SCF complex, and instead FBXO45 associates with the RING-finger ligase PAM/MycBP2 (and SKP1) to assemble an E3 complex essential for neural development, including diaphragm innervation, neuromuscular junction synapse formation, axon tract development, and neuronal migration (PMID:19398581). The protein recognizes substrates through two distinct modules—its SPRY domain and its F-box domain—allowing it to engage a broad substrate repertoire (PMID:25460509). In the nervous system it controls synaptic strength by ubiquitylating the vesicle-priming factor Munc13-1 (PMID:19996097) and guides radial neuron migration by binding SPRY motifs in the extracellular domain of N-cadherin via a nonclassical secretion route (PMID:32341084). FBXO45 directs substrates to proteasomal degradation through diverse ubiquitin linkages, including K48-linked chains on EMT transcription factors such as ZEB1 (PMID:33966034) and K6-linked chains on the STEP phosphatase NP-STEP46 (PMID:35838331), and can also route substrates to p62/SQSTM1-dependent autophagy, as for phosphorylated HIV-1 Tat (PMID:39936917). Through degradation of tumor suppressors and apoptotic regulators—p73 (PMID:19581926), Par-4 (PMID:24992930), FBXW7 during mitotic arrest (PMID:31285543), and BIM (PMID:38773471)—and activation of oncogenic effectors such as IGF2BP1 (PMID:34779401), FBXO45 functions as a context-dependent regulator of apoptosis, mitotic fate, and tumor progression. It additionally maintains genomic integrity by forming an FBXO45-UPF1-PPP6C complex that stabilizes replication-dependent histone mRNAs, with its own abundance gated by CDK1-mediated phosphorylation for cell-cycle-regulated turnover (PMID:39672818).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2009 High

    Established that FBXO45 is not a canonical SCF adaptor but instead partners with the RING ligase PAM/Phr1, defining the architecture of a novel E3 complex required for nervous system development.

    Evidence Proteomics, knockout mice, and Fbxo45/Phr1 genetic epistasis

    PMID:19398581

    Open questions at the time
    • Did not enumerate the developmental substrates degraded by the complex
    • Cul1-independence shown but the full subunit composition of the active ligase not biochemically reconstituted
  2. 2009 High

    Identified the first defined degradation substrates, showing FBXO45 controls apoptotic/tumor-suppressor output (p73) and synaptic transmission (Munc13-1) through ubiquitin-proteasome targeting.

    Evidence Co-IP, in vitro ubiquitylation, siRNA, and mEPSC electrophysiology in neurons

    PMID:19581926 PMID:19996097

    Open questions at the time
    • Recognition motifs on p73 and Munc13-1 not mapped
    • Whether degradation requires PAM/MycBP2 catalytic activity not tested in these reports
  3. 2014 High

    Revealed the SPRY domain as a substrate-docking module and uncovered a non-degradative N-cadherin function, broadening FBXO45 roles beyond proteasomal turnover.

    Evidence MS screens, SPRY consensus-motif identification for Par-4, Co-IP and proteolysis assays for N-cadherin

    PMID:24992930 PMID:25143387

    Open questions at the time
    • Mechanism by which FBXO45 limits N-cadherin proteolysis without ubiquitinating it unclear
    • Relative contributions of SPRY vs F-box recognition not yet generalized
  4. 2015 Medium

    Defined dual substrate-recognition logic and named the SPF complex, linking FBXO45 to EMT control by degrading core EMT transcription factors via distinct domains.

    Evidence Co-IP, ubiquitination assays, domain mutagenesis (SPRY for Zeb2, F-box for Snai1/2/Twist1), miR-27a* regulation; TAP-MS Hey1 interaction and nuclear redirection

    PMID:25460509 PMID:26068074

    Open questions at the time
    • Hey1-driven nuclear relocalization not connected to specific nuclear substrates
    • In vivo relevance of EMT-TF degradation not tested here
  5. 2018 Medium

    Connected FBXO45 substrate targeting to physiological signaling by showing inflammatory TNF-α suppresses Fbxo45-mediated Munc13-1 turnover to drive pain.

    Evidence Rat neuropathic model, Co-IP, ubiquitination, mEPSC, intrathecal TNF-α and siRNA

    PMID:30042425

    Open questions at the time
    • Molecular link between TNF-α signaling and reduced Fbxo45 activity not resolved
    • Single in vivo model
  6. 2019 High

    Placed FBXO45 in mitotic fate control by demonstrating it degrades the tumor suppressor FBXW7 during prolonged mitotic arrest to promote slippage and survival.

    Evidence Reciprocal Co-IP, ubiquitination, FBXW7 motif mutagenesis, time-lapse imaging

    PMID:31285543

    Open questions at the time
    • Trigger restricting this activity to mitotic arrest not defined
    • Whether MYCBP2 catalysis is rate-limiting not tested
  7. 2021 Medium

    Expanded FBXO45 outputs to non-degradative activation and revealed regulation of its own stability, with IGF2BP1 site-specific ubiquitination driving tumorigenesis and DNAJB9 suppressing FBXO45 auto-ubiquitination.

    Evidence Site-specific ubiquitination mutagenesis (IGF2BP1 K190/K450), transgenic mice, K48 ubiquitination assays for ZEB1, in vivo metastasis

    PMID:33966034 PMID:34779401

    Open questions at the time
    • How a single adaptor produces activating vs degradative ubiquitination not mechanistically unified
    • Auto-ubiquitination regulators beyond DNAJB9 unknown
  8. 2022 Medium

    Demonstrated diverse linkage chemistry and broad substrate scope across cancers and innate immunity, including K6-linked NP-STEP46 degradation and IFNLR1 turnover that dampens interferon signaling.

    Evidence Linkage-specific ubiquitination assays, site mutagenesis (IFNLR1 K319/K320R), proximity-ligation screens, kinase enhancement (NEK6), xenografts for USP49/GGNBP2; RBX1-driven FBXO45 destabilization

    PMID:35279684 PMID:35802537 PMID:35838331 PMID:36127399 PMID:36379255

    Open questions at the time
    • Determinants selecting K6 vs K48 linkage not defined
    • How kinases like NEK6 and ligases like RBX1 are integrated with the SPF complex remains incomplete
  9. 2024 High

    Identified a non-ligase scaffolding function in genome maintenance and clarified cell-cycle control of FBXO45 itself, with the FBXO45-UPF1-PPP6C complex protecting histone mRNAs and CDK1 phosphorylation gating FBXO45 degradation.

    Evidence AT2-specific conditional knockout mice, ternary-complex Co-IP, CDK1 kinase and phosphatase assays, histone mRNA stability, spontaneous tumorigenesis; BIM degradation Co-IP/CHX in breast cancer

    PMID:38773471 PMID:39672818

    Open questions at the time
    • How FBXO45 switches between ligase-adaptor and PPP6C-scaffold roles is unresolved
    • Structural basis of the UPF1-PPP6C ternary complex unknown
  10. 2025 Medium

    Extended FBXO45 to autophagic substrate routing, transcriptional pathway placement, and additional disease contexts, including p62-dependent degradation of HIV-1 Tat and SETD7-p53-driven FBXO45 transcription degrading GPX4.

    Evidence TurboID, autophagy-pathway mutagenesis (Tat S62A), SETD7 knockout mice, site-specific ubiquitination (TFG K103), metabolic and xenograft assays for DUSP2/Erbin

    PMID:39936917 PMID:40275362 PMID:40637745 PMID:41030651 PMID:41285235

    Open questions at the time
    • What dictates proteasomal vs autophagic routing of FBXO45 substrates is undefined
    • DUSP2 and Erbin findings lack domain/site mapping

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how a single adaptor integrates SPRY- versus F-box-based recognition, selects among ubiquitin linkage types and degradation routes (proteasome vs autophagy), and toggles between E3-adaptor and non-catalytic scaffold roles.
  • No structure of FBXO45 bound to PAM/MycBP2-SKP1 or substrates
  • No unifying model linking substrate identity to linkage type and degradation pathway

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0060090 molecular adaptor activity 3 GO:0098772 molecular function regulator activity 3
Localization
GO:0005634 nucleus 3 GO:0005576 extracellular region 1 GO:0005829 cytosol 1
Pathway
GO:0140096 catalytic activity, acting on a protein 3
Partners
FBXW7IGF2BP1MYCBP2N-CADHERINPPP6CSKP1UPF1USP49
Complex memberships
FBXO45-MYCBP2/PAM E3 ligaseFBXO45-UPF1-PPP6C complexSPF (Skp1-Pam-Fbxo45) ubiquitin ligase complex

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 FBXO45 does not form a canonical SCF complex due to an amino acid substitution in the consensus sequence for Cul1 binding; instead, it specifically associates with PAM/Phr1 (a RING finger-type ubiquitin ligase) to form a novel Fbxo45-PAM ubiquitin ligase complex required for neural development, including innervation of the diaphragm, synapse formation at neuromuscular junctions, axon fiber tract development, and neuronal migration. Proteomics/mass spectrometry, knockout mice, genetic epistasis (Fbxo45-/- and Phr1-/- phenotype comparison) Molecular and cellular biology High 19398581
2009 FBXO45 (human ortholog of C. elegans FSN-1) binds specifically to p73 and triggers its proteasome-dependent degradation via SCF(FBXO45)-mediated ubiquitylation both in vivo and in vitro; siRNA-mediated depletion of FBXO45 stabilizes p73 and induces p53-independent cell death. Co-immunoprecipitation, in vitro ubiquitylation assay, siRNA knockdown, proteasome inhibitor rescue Oncogene High 19581926
2009 Fbxo45 induces ubiquitin-mediated proteasomal degradation of the synaptic vesicle-priming factor Munc13-1 at synapses; knockdown of Fbxo45 in primary cultured hippocampal neurons increases the frequency of miniature excitatory postsynaptic currents. RNAi knockdown, electrophysiology (mEPSC recording), ubiquitination assay, Western blot The Journal of biological chemistry High 19996097
2014 Fbxo45 interacts with Par-4 (tumor suppressor) through its SPRY domain via a short consensus sequence motif in the cytoplasm, mediating Par-4 ubiquitylation and proteasomal degradation; Fbxo45 silencing stabilizes Par-4 and increases apoptosis, while a Par-4 mutant unable to bind Fbxo45 is stabilized and enhances staurosporine-induced apoptosis. Immunopurification, mass spectrometry, co-immunoprecipitation, ubiquitination assay, RNAi knockdown, site-directed mutagenesis, apoptosis assay Cell death and differentiation High 24992930
2014 Fbxo45 interacts with N-cadherin; Fbxo45 depletion results in enhanced proteolysis of N-cadherin (not ubiquitination-mediated degradation), while ectopic Fbxo45 expression decreases N-cadherin proteolysis, and Fbxo45 depletion impairs neuronal differentiation and neuronal process formation. Mass spectrometry-based proteomic screen, co-immunoprecipitation, RNAi knockdown, ectopic overexpression, Western blot, neuronal differentiation assay The Journal of biological chemistry Medium 25143387
2015 The atypical Skp1-Pam-Fbxo45 (SPF) E3 ligase complex promotes ubiquitin-proteasome-dependent degradation of core EMT transcription factors (Zeb1/2, Snai1/2, Twist1); Fbxo45 recognizes Zeb2 via its SPRY domain and Snai1, Snai2, and Twist1 via its F-box domain; K48-linked ubiquitination of Zeb2 requires a functional SBD domain; miR-27a* downregulates Fbxo45 expression, preventing EMT-TF degradation. Co-immunoprecipitation, ubiquitination assay, domain mutagenesis, miRNA overexpression, Western blot Oncotarget Medium 25460509
2015 Hey1 directly interacts with FBXO45 and indirectly with SKP1 via FBXO45; Hey1 expression induces translocation of FBXO45 and PAM into the nucleus, potentially redirecting the ubiquitin ligase complex to nuclear targets; no evidence for FBXO45-dependent ubiquitination of Hey1 itself. Tandem affinity purification, mass spectrometry, co-immunoprecipitation, subcellular fractionation/localization, overexpression PloS one Medium 26068074
2018 Spinal TNF-α impedes Fbxo45-dependent Munc13-1 ubiquitination in the dorsal horn; neuropathic injury decreases spinal Fbxo45 expression, Fbxo45-Munc13-1 co-precipitation, and Munc13-1 ubiquitination, leading to accumulation of Munc13-1 at presynaptic areas and increased excitatory neurotransmission; focal knockdown of spinal Fbxo45 in naive animals produces allodynia. Rat behavioral model, co-immunoprecipitation, ubiquitination assay, electrophysiology (mEPSC), TNF-α intrathecal injection, siRNA knockdown Cell death & disease Medium 30042425
2019 FBXO45-MYCBP2 E3 ubiquitin ligase targets FBXW7 for ubiquitylation and proteasomal degradation specifically during prolonged mitotic arrest; FBXO45 binds a conserved acidic N-terminal motif of FBXW7; this interaction promotes mitotic slippage and prevents mitotic cell death, thereby counteracting FBXW7 tumor suppressor function. Co-immunoprecipitation, ubiquitination assay, time-lapse microscopy, RNAi, site-directed mutagenesis of FBXW7 motif Cell death and differentiation High 31285543
2020 Fbxo45 binds SPRY motifs in the extracellular domain of N-cadherin (not involved in homophilic cell-cell adhesion); Fbxo45 appears to be secreted by a nonclassical mechanism independent of ER-to-Golgi transport; both Fbxo45 suppression and N-cadherin SPRY-motif mutation inhibit radial neuron migration in vivo. Proximity ligation, affinity purification proteomics, in utero electroporation/in vivo migration assay, SPRY-motif mutagenesis of N-cadherin, nonclassical secretion analysis Molecular and cellular biology High 32341084
2021 FBXO45 promotes IGF2BP1 ubiquitination at Lys190 and Lys450 sites, leading to IGF2BP1 activation and subsequent upregulation of PLK1 expression, inducing cell proliferation and liver tumorigenesis; PLK1 inhibition or IGF2BP1 knockdown blocks FBXO45-driven tumorigenesis. Co-immunoprecipitation, ubiquitination assay with site-specific mutagenesis (Lys190/450), transgenic mice, in vitro and in vivo functional assays, IHC eLife High 34779401
2021 DNAJB9 stabilizes FBXO45 protein by suppressing FBXO45 self-ubiquitination; stabilized FBXO45 promotes Lys48-linked polyubiquitination of ZEB1, leading to its degradation and inhibition of EMT. Co-immunoprecipitation, ubiquitination assay, overexpression/knockdown, in vivo metastasis assay Cell death & disease Medium 33966034
2022 Fbxo45 binds to USP49 via its SPRY domain and, enhanced by NEK6 kinase, mediates USP49 ubiquitination and proteasomal degradation, thereby promoting pancreatic cancer cell viability and motility. Co-immunoprecipitation, ubiquitination assay, kinase (NEK6) co-expression, RNAi knockdown, xenograft mouse model Cell death & disease Medium 35279684
2022 FBXO45 induces K6-linked polyubiquitination of NP-STEP46 (active form of STEP phosphatase), leading to its proteasomal degradation in the nucleus, thereby sustaining phospho-ERK levels and promoting NSCLC tumor growth; FBXO45 silencing sensitizes cells to EGFR-TKI. In vitro and in vivo ubiquitination assay (K6 linkage-specific), co-immunoprecipitation, RNAi, xenograft model, ERK phosphorylation measurement Molecular oncology Medium 35838331
2022 Fbxo45 binds GGNBP2 via its SPRY domain and targets it for ubiquitination and proteasomal degradation in esophageal squamous cell carcinoma cells, promoting tumor growth and invasion. Co-immunoprecipitation, ubiquitination assay, domain analysis (SPRY), RNAi knockdown, overexpression, xenograft mouse model Oncogene Medium 36127399
2022 FBXO45 binds IFNLR1 (IFN-λ receptor) intracellular domain and mediates its polyubiquitination and proteasomal degradation; K319R/K320R IFNLR1 mutant shows reduced polyubiquitination and greater stability; FBXO45 expression is induced by influenza infection and negatively regulates interferon-stimulated gene expression. Proximity ligation biotin screen, co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis (K319R/K320R), siRNA knockdown, overexpression The Journal of biological chemistry High 36379255
2022 RBX1 directly binds FBXO45 and promotes its ubiquitination and degradation; this destabilization of FBXO45 leads to accumulation of TWIST1 and enhanced EMT/metastasis in triple-negative breast cancer. Co-immunoprecipitation, ubiquitination assay, RNAi knockdown, overexpression Aging Medium 35802537
2024 FBXO45 is a cell-cycle-regulated protein degraded upon CDK1-mediated phosphorylation during S/G2 phase; during S phase or DNA damage repair, FBXO45 binds UPF1 and recruits the phosphatase PPP6C to inhibit UPF1 phosphorylation, thereby preventing degradation of replication-dependent histone mRNAs and ensuring adequate histone supply; loss of FBXO45 in AT2 cells causes UPF1 hyperphosphorylation, histone insufficiency, genomic instability, and spontaneous lung adenocarcinoma in mice. Conditional knockout mice (AT2-specific), co-immunoprecipitation (FBXO45-UPF1-PPP6C), phosphorylation assays, histone mRNA stability assays, CDK1 kinase assay, genomic instability analysis Cell death and differentiation High 39672818
2024 FBXO45 interacts with BIM and mediates its ubiquitination and proteasomal degradation; knockdown of FBXO45 inhibits breast cancer cell proliferation via BIM pathway stabilization and induces apoptosis. Co-immunoprecipitation, ubiquitination assay, cycloheximide chase assay, RNAi knockdown, overexpression, xenograft model BMC cancer Medium 38773471
2025 FBXO45 mediates ubiquitination of HIV-1 Tat (requiring Tat phosphorylation at S62), directing it to SQSTM1/p62-dependent autophagic degradation; FBXO45 suppresses HIV-1 replication and maintains viral latency; FBXO45 overexpression attenuates viral rebound after antiretroviral therapy withdrawal. TurboID proximity labeling, co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis (S62A Tat, autophagy pathway), HIV-1 replication assay, siRNA knockdown Journal of virology Medium 39936917
2025 SETD7 promotes p53 mono-methylation which activates FBXO45 transcription; FBXO45 then mediates proteasomal degradation of GPX4, leading to lipid peroxidation and oxidative stress-induced endothelial dysfunction; SETD7 deficiency reduces FBXO45 transcription, inhibiting GPX4 degradation. SETD7 knockout mice, endothelial-specific AAV knockdown, co-immunoprecipitation, Western blot, lipid peroxidation assay, glucose-stressed endothelial cells Cardiovascular diabetology Medium 40275362
2025 FBXO45 promotes Lys103 ubiquitination of TFG (Trk-fused gene), enhancing TFG stability; stabilized TFG facilitates binding of ATF2 transcription factor, upregulating NF-κB p65 expression and promoting migration, invasion, and lung metastasis of TP53-mutant HCC cells. Co-immunoprecipitation, ubiquitination assay with site-specific mutagenesis (Lys103), orthotopic xenograft model, ATF2/NF-κB reporter assays, siRNA knockdown, overexpression JHEP reports Medium 41030651
2025 FBXO45 interacts with and ubiquitinates DUSP2, leading to its proteasomal degradation, ERK1/2 activation, and enhanced glycolysis in cervical cancer cells. Co-immunoprecipitation, ubiquitination assay, overexpression/knockdown, Seahorse metabolic assay, xenograft model Naunyn-Schmiedeberg's archives of pharmacology Low 40637745
2025 FBXO45 promotes ubiquitination and degradation of Erbin in clear cell renal cell carcinoma, enhancing cell viability, motility, and sunitinib resistance; Fbxo45 expression is negatively correlated with Erbin expression in ccRCC. Co-immunoprecipitation (implied by negative correlation and functional rescue), overexpression/knockdown, xenograft model, sunitinib sensitivity assay Experimental cell research Low 41285235

Source papers

Stage 0 corpus · 34 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 Fbxo45 forms a novel ubiquitin ligase complex and is required for neuronal development. Molecular and cellular biology 110 19398581
2009 The F-box protein FBXO45 promotes the proteasome-dependent degradation of p73. Oncogene 87 19581926
2015 Atypical ubiquitin E3 ligase complex Skp1-Pam-Fbxo45 controls the core epithelial-to-mesenchymal transition-inducing transcription factors. Oncotarget 80 25460509
2009 Fbxo45, a novel ubiquitin ligase, regulates synaptic activity. The Journal of biological chemistry 74 19996097
2021 Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation. eLife 60 34779401
2022 Fbxo45 facilitates pancreatic carcinoma progression by targeting USP49 for ubiquitination and degradation. Cell death & disease 57 35279684
2014 Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival. Cell death and differentiation 49 24992930
2021 DNAJB9 suppresses the metastasis of triple-negative breast cancer by promoting FBXO45-mediated degradation of ZEB1. Cell death & disease 44 33966034
2019 FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation. Cell death and differentiation 42 31285543
2020 FBXO45 is a potential therapeutic target for cancer therapy. Cell death discovery 33 32655893
2022 Fbxo45 promotes the malignant development of esophageal squamous cell carcinoma by targeting GGNBP2 for ubiquitination and degradation. Oncogene 31 36127399
2014 Fbxo45 inhibits calcium-sensitive proteolysis of N-cadherin and promotes neuronal differentiation. The Journal of biological chemistry 22 25143387
2022 CACNA1C-AS2 inhibits cell proliferation and suppresses cell migration and invasion via targeting FBXO45 and PI3K/AKT/mTOR pathways in glioma. Apoptosis : an international journal on programmed cell death 21 36038736
2020 Fbxo45 Binds SPRY Motifs in the Extracellular Domain of N-Cadherin and Regulates Neuron Migration during Brain Development. Molecular and cellular biology 19 32341084
2005 Characterization of estrogen-induced F-box protein FBXO45. Oncology reports 19 16012741
2018 Spinal TNF-α impedes Fbxo45-dependent Munc13-1 ubiquitination to mediate neuropathic allodynia in rats. Cell death & disease 18 30042425
2014 Novel rare variants in F-box protein 45 (FBXO45) in schizophrenia. Schizophrenia research 15 24878430
2022 Fbxo45-mediated NP-STEP46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer. Molecular oncology 14 35838331
2018 A genome-wide association study of coping behaviors suggests FBXO45 is associated with emotional expression. Genes, brain, and behavior 14 29665250
2022 E3 ubiquitin ligase RBX1 drives the metastasis of triple negative breast cancer through a FBXO45-TWIST1-dependent degradation mechanism. Aging 10 35802537
2022 The E3 ligase subunit FBXO45 binds the interferon-λ receptor and promotes its degradation during influenza virus infection. The Journal of biological chemistry 10 36379255
2015 Hey bHLH Proteins Interact with a FBXO45 Containing SCF Ubiquitin Ligase Complex and Induce Its Translocation into the Nucleus. PloS one 9 26068074
2023 LncRNA MEG8 ameliorates Parkinson's disease neuro-inflammation through miR-485-3p/FBXO45 axis. Acta neurologica Belgica 8 37814093
2025 SETD7 drives diabetic endothelial dysfunction through FBXO45-mediated GPX4 ubiquitylation. Cardiovascular diabetology 7 40275362
2022 MiR-30a-5p hampers proliferation of lung squamous cell carcinoma through targeting FBXO45. Histology and histopathology 6 35098525
2024 Fbxo45 facilitates the malignant progression of breast cancer by targeting Bim for ubiquitination and degradation. BMC cancer 5 38773471
2025 FBXO45 restricts HIV-1 replication by inducing SQSTM1/p62-mediated autophagic degradation of Tat. Journal of virology 2 39936917
2024 Loss of Fbxo45 in AT2 cells leads to insufficient histone supply and initiates lung adenocarcinoma. Cell death and differentiation 2 39672818
2025 The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. Cancer discovery 1 39820335
2025 Fbxo45 promotes cell viability, invasion and sunitinib resistance of clear cell renal cell carcinoma by targeting Erbin. Experimental cell research 1 41285235
2024 FBXO45 Knockdown Restrains the Progression of Bladder Cancer via the ERK/Cyclin D1/CDK4 Pathway. Archivos espanoles de urologia 1 39238305
2025 FBXO45 enhances cell viability and glycolysis in cervical cancer via DUSP2 ubiquitination-mediated ERK1/2 activation. Naunyn-Schmiedeberg's archives of pharmacology 0 40637745
2025 Elevated FBXO45 promotes TFG ubiquitination and drives lung metastasis of hepatocellular carcinoma. JHEP reports : innovation in hepatology 0 41030651
2024 FBXO45 levels regulated ferroptosis renal tubular epithelial cells in a model of diabetic nephropathy by PLK1. Open medicine (Warsaw, Poland) 0 38841177

Missed literature

Know a paper Affinage missed for FBXO45? Flag it for the maintainers and the community.

No submissions yet.